Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard.
The only sensitive and convenient assay to assess the biological activity of low molecular weight heparins (LMWHs) is based on the potentiation of activated factor Xa inhibition. Several procedures for measuring the socalled anti Xa activity have been proposed. In this collaborative study including eight laboratories, we have used four different assays (three amidolytic and one clotting based methods) for measuring the anti Xa activity of ex vivo samples obtained after injecting three different LMWHs. The dispersion of the results obtained by calibration against standard heparin could be reduced by using any of the three LMWHs for calibration. A coefficient of variation less than 0.20 between values obtained in different laboratories using a variety of methods seems acceptable. However it is necessary to refer to a common international standard for expressing the results in units and to define, for each of the three products, the therapeutic range.
Sié
P
P
Haemostasis laboratories, Hôpital Purpan, Toulouse, France.
Aillaud
M F
MF
de Prost
D
D
Droullé
C
C
Forestier
F
F
Guedj
P
P
Juhan-Vague
I
I
Polack
B
B
Potron
G
G
Roncato
M
M
D015951:Factor Xa; D006495:Heparin, Low-Molecular-Weight / Q000097:blood* / Q000592:standards; D006801:Humans; D012015:Reference Standards; D015842:Serine Proteinase Inhibitors
D006495:Heparin, Low-Molecular-Weight; D015842:Serine Proteinase Inhibitors; D015951:Factor Xa